117 related articles for article (PubMed ID: 33058542)
1. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF
Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542
[TBL] [Abstract][Full Text] [Related]
2. SOX13 is a novel prognostic biomarker and associates with immune infiltration in breast cancer.
Gao T; Jiang B; Zhou Y; He R; Xie L; Li Y
Front Immunol; 2024; 15():1369892. PubMed ID: 38707897
[TBL] [Abstract][Full Text] [Related]
3. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract][Full Text] [Related]
4. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
Front Immunol; 2020; 11():560074. PubMed ID: 33304345
[TBL] [Abstract][Full Text] [Related]
5. Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.
Finsterbusch K; van Diest PJ; Focke CM
Breast Cancer Res Treat; 2024 Jun; 205(2):413-421. PubMed ID: 38453779
[TBL] [Abstract][Full Text] [Related]
6. RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancer.
Yi J; Liu L; Chen Y; Ding T; Fan P; Yu J; Zeng J
FASEB J; 2024 May; 38(9):e23624. PubMed ID: 38747001
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of the Expression and Prognosis for
Wu ZH; Zhang YJ; Yue JX; Zhou T
Cell Transplant; 2020; 29():963689720962479. PubMed ID: 32990024
[TBL] [Abstract][Full Text] [Related]
8. PROS1, a clinical prognostic biomarker and tumor suppressor, is associated with immune cell infiltration in breast cancer: A bioinformatics analysis combined with experimental verification.
He T; Sun X; Wu C; Yao L; Zhang Y; Liu S; Jiang Y; Li Y; Wang M; Xu Y
Cell Signal; 2023 Dec; 112():110918. PubMed ID: 37827342
[TBL] [Abstract][Full Text] [Related]
9. BECN1 mRNA expression in breast cancer tissue; significant correlation to tumor grade.
Aglan SA; Awad AM; Elwany YN; Shawky S; Salam RMA; Omar RS; Ghazala RAM; Soliman NA; Khedr MI; Kandil LS; Sultan M; Hamed Y; Kandil NS
Mol Genet Genomics; 2024 May; 299(1):56. PubMed ID: 38787424
[TBL] [Abstract][Full Text] [Related]
10. The role of transcription factor FOXA1/C2/M1/O3/P1/Q1 in breast cancer.
Yuan H; Liang Y; Hu S; Chen J; You J; Jiang J; Luo M; Zeng M
Medicine (Baltimore); 2024 Apr; 103(15):e37709. PubMed ID: 38608123
[TBL] [Abstract][Full Text] [Related]
11. The role of immune infiltrates as prognostic biomarkers in patients with breast cancer.
Baxevanis CN; Sofopoulos M; Fortis SP; Perez SA
Cancer Immunol Immunother; 2019 Oct; 68(10):1671-1680. PubMed ID: 30905043
[TBL] [Abstract][Full Text] [Related]
12.
Zang Z; Yin Y; Liu C; Zhu Q; Huang X; Li H; Yang R
Epigenetics; 2024 Dec; 19(1):2352683. PubMed ID: 38723244
[TBL] [Abstract][Full Text] [Related]
13. Are embryonic stem cell markers and ALDH1A1 relevant in the context of breast cancer estrogen positivity?
Mousa NA; Hussein A; Elemam NM; Mohammed G; Elwany M; Basha T; AlHammadi AA; Majzob RS; Talaat IM
Cancer Med; 2024 Feb; 13(3):e7004. PubMed ID: 38400679
[TBL] [Abstract][Full Text] [Related]
14. Differential role of glucocorticoid receptor based on its cell type specific expression on tumor cells and infiltrating lymphocytes.
Snijesh VP; Nimbalkar VP; Patil S; Rajarajan S; Anupama CE; Mahalakshmi S; Alexander A; Soundharya R; Ramesh R; Srinath BS; Jolly MK; Prabhu JS
Transl Oncol; 2024 Jul; 45():101957. PubMed ID: 38643748
[TBL] [Abstract][Full Text] [Related]
15. The Tumor Immune Microenvironment in Breast Cancer Progression.
Otterlei Fjørtoft M; Huse K; Rye IH
Acta Oncol; 2024 May; 63():359-367. PubMed ID: 38779867
[TBL] [Abstract][Full Text] [Related]
16. Association of ADP‑ribosylation factor family genes with prognosis and immune infiltration of breast cancer.
Yang L; Zhang S; Zheng L; Kong F; Pu P; Li X; Jia L
Oncol Lett; 2024 Jun; 27(6):280. PubMed ID: 38699662
[TBL] [Abstract][Full Text] [Related]
17. Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer.
Tinholt M; Stavik B; Tekpli X; Garred Ø; Borgen E; Kristensen V; Sahlberg KK; Sandset PM; Iversen N
Oncoimmunology; 2020 Sep; 9(1):1824644. PubMed ID: 33457104
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
Ren H; Wang Z; Zhang L; Zhu G; Li F; Chen B
BMC Cancer; 2024 Mar; 24(1):367. PubMed ID: 38515057
[TBL] [Abstract][Full Text] [Related]
19. Identifying SLC2A6 as the novel protective factor in breast cancer by TP53-related genes affecting M1 macrophage infiltration.
Dai C; Man Y; Zhang L; Zhang X; Xie C; Wang S; Zhang Y; Guo Q; Zou L; Hong H; Jiang L; Shi Y
Apoptosis; 2024 Apr; ():. PubMed ID: 38622369
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatics analysis of GPS1 expression and biological function in breast cancer.
Wei H; Niu Z; Ji R; Jiang W; Tang J; Meng Z; Cao X; Zhang X; Liu X
J Cancer Res Clin Oncol; 2024 Jan; 150(2):52. PubMed ID: 38289496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
